目的：比较洛铂/顺铂联合依托泊苷治疗初治小细胞肺癌的疗效和安全性。方法：60 例初治小细胞肺癌患者随机均分为

观察组和对照组。观察组患者给予注射用洛铂30 mg/m2，加入5％葡萄糖注射液500 ml 中，d1，静脉滴注1 h+ 依托泊苷注射液100

mg/m2，加入0.9％氯化钠注射液500 ml中，d1～3，静脉滴注1 h。对照组患者给予注射用顺铂25 mg/m2，加入0.9％氯化钠注射液500

ml 中，d1～3，静脉滴注1 h+ 依托泊苷注射液（用法用量同观察组）。两组患者均以3 周为1 个化疗周期。观察两组患者的临床疗效

及毒性反应。结果：两组患者均完成2 个周期以上的治疗。两组患者总有效率比较，差异无统计学意义（P＞0.05）。观察组患者恶

心呕吐、腹泻Ⅰ～Ⅳ度总发生率均显著低于对照组，差异均有统计学意义（P＜0.05）。结论：洛铂/顺铂联合依托泊苷治疗初治小

细胞肺癌的疗效相当，但在安全性方面洛铂优于顺铂。

OBJECTIVE：To compare the efficacy of lobaplatin / cisplatin combined with etoposide in the treatment of primary

small cell lung cancer. METHODS：60 patients with small cell lung cancer were randomly divided into observation group and control

group. Observation group was given 30 mg/m2 Lobaplatin injection，adding into 500 ml 5％ Glucose injection，d1，by intravenous

infusion for 1 h+100 mg/m2 Etoposide injection，adding into 500 ml 0.9％ Sodium chloride injection，d1-3，by intravenous infusion

for 1 h. Control group was given 25 mg/m2 Cisplatin injection，adding into 500 ml 0.9％ Sodium chloride injection，d1-3，by intravenous

infusion for 1 h+Etoposide injection（the same dose with observation group）. 3-week was regarded as a chemotherapy cycle.

The clinical efficacy and toxicities in 2 groups were observed. RESULTS：There were more than 2 cycles for both groups.

There was no significant difference in the total effective rate between 2 groups（P＞0.05），and the incidences of nausea，vomiting

and diarrhea in observation group were significantly lower than control group，the differences were statistically significant（P＜

0.05）. CONCLUSIONS：Lobaplatin / cisplatin combined with etoposide has similar efficacy in the treatment of primary small cell

lung cancer，and lobaplatin has better safety.